A5012643650- Lipoproteins and Cardiovascular Health
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Diabetes, Cardiovascular Risks, and Lipoproteins
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- Cancer, Lipids, and Metabolism
- Diabetes Treatment and Management
- Bladder and Urothelial Cancer Treatments
- HIV/AIDS Research and Interventions
- Urinary and Genital Oncology Studies
- Immune Cell Function and Interaction
- Antiplatelet Therapy and Cardiovascular Diseases
- Tissue Engineering and Regenerative Medicine
- Cancer Treatment and Pharmacology
- Pulmonary Hypertension Research and Treatments
- Adipokines, Inflammation, and Metabolic Diseases
- Epigenetics and DNA Methylation
- Ginkgo biloba and Cashew Applications
- Pneumocystis jirovecii pneumonia detection and treatment
- Systemic Lupus Erythematosus Research
- Atherosclerosis and Cardiovascular Diseases
- Clinical practice guidelines implementation
- Menopause: Health Impacts and Treatments
- Esophageal Cancer Research and Treatment
Esperion Therapeutics (United States)
2021-2024
Cleveland Clinic
2024
Imperial College London
2021
Regeneron (United States)
2015-2020
Uppsala University
2020
University of Colorado Denver
2020
Sanofi (United States)
2016-2019
Clinical Research Institute
2019
Duke Medical Center
2019
RELX Group (United States)
2018
Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes remain uncertain. Download PDF the Research Summary. We conducted double-blind, randomized, placebo-controlled trial involving patients who were unable or unwilling to take statins owing unacceptable ("statin-intolerant" patients) had, at high risk for, disease. The assigned...
ABSTRACT Mathematical models provide an understanding of in vivo replication kinetics human immunodeficiency virus type 1 (HIV-1). With a novel intervention designed for increased potency, we have more accurately deduced the half-lives virus-producing CD4 + T cells, 0.7 day, and generation time HIV-1 vivo, approximately 2 days, confirming dynamic nature replication.
Background: Female patients have historically received less aggressive lipid management than male patients. Contemporary care patterns and the potential causes for these differences are unknown. Methods Results: Examining Patient Provider Assessment of Lipid Management Registry—a nationwide registry outpatients with or at risk atherosclerotic cardiovascular disease—we compared use statin therapy, guideline-recommended dosing, reasons undertreatment. We specifically analyzed sex in treatment...
Background Many adults eligible for statin therapy cardiovascular disease prevention are untreated. Our objective was to investigate patient‐reported reasons underutilization, including noninitiation, refusal, and discontinuation. Methods Results This study included the 5693 recommended in PALM (Patient Provider Assessment of Lipid Management) registry. Patient surveys evaluated experience, declining or discontinuing statins, beliefs about statins risk. Overall, 1511 (26.5%) were not on...
The effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients without a prior event (primary prevention) have not been fully described.To determine the primary prevention patients.This masked, randomized clinical trial enrolled 13 970 (enrollment December 2016 to August 2019 at 1250 centers 32 countries), including 4206 patients.Participants were oral acid, 180 mg daily (n = 2100), or matching placebo 2106).The efficacy measure was time from randomization first...
Among patients treated with statin therapy to guideline-recommended cholesterol levels, residual inflammatory risk assessed by high-sensitivity C-reactive protein (hsCRP) is at least as strong a predictor of future cardiovascular events low-density lipoprotein (LDLC). Whether these relationships are present among statin-intolerant higher LDLC levels uncertain but has implications for the choice preventive therapies, including bempedoic acid, an agent that reduces both and hsCRP.
Statins reduce LDL cholesterol and cardiovascular events among those with or without diabetes but have been reported to increase new-onset diabetes. The CLEAR Outcomes trial demonstrated that bempedoic acid reduced the risk of major adverse statin-intolerant patients at high risk. In this prespecified analysis, our dual aims were evaluate benefits acid, an ATP-citrate lyase inhibitor, in individuals diabetes, HbA
Abstract Chronic low-degree inflammation is a hallmark of atherosclerotic cardiovascular (CV) disease. To assess the effect lipid-lowering therapies on C-reactive protein (CRP), biomarker inflammation, we conducted meta-analysis according to PRISMA guidelines. Databases were searched from inception July 2023. Inclusion criteria were: (i) randomized controlled trials (RCTs) in human, Phase II, III, or IV; (ii) English language; (iii) comparing drugs vs. placebo; (iv) reporting effects CRP...
Elevated lipoprotein(a) [Lp(a)] is independently associated with increased cardiovascular risk. However, treatment options for elevated Lp(a) are limited. Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9, reduced low-density lipoprotein cholesterol (LDL-C) by up 62% from baseline in phase 3 studies, adverse event rates similar between alirocumab and controls. We evaluated the effect of on serum using pooled data ODYSSEY program: 4,915 patients...
Individuals with chronic kidney disease are at increased risk of premature cardiovascular disease. Among them, many elevated low-density lipoprotein cholesterol (LDL-C) unable to achieve optimal LDL-C on statins and require additional lipid-lowering therapy. To study this, we compared the LDL-C-lowering efficacy safety alirocumab in individuals hypercholesterolemia impaired renal function, defined as eGFR 30-59 ml/min/1.73 m2, those without function ≥60 m2. A total 4629 hypercholesterolemic...
Sixteen subjects were treated with highly active antiretroviral therapy within 120 days of the onset symptoms newly acquired human immunodeficiency virus type 1 (HIV-1) infection. Eleven 16 participated in an adjunctive therapeutic vaccine trial. After a mean 3.2 years treatment, they elected to discontinue therapy. Virus rebound occurred all and was followed by spontaneous, transient although significant reduction log plasma HIV-1 RNA level, ranging from 0.3 3.1 log(10) copies/mL. Despite...
Objective To assess temporal changes in prevalence of transmitted HIV-1 drug resistance a homogeneous cohort newly infected individuals. Methods Pretreatment genotypic and phenotypic was tested 154 subjects with primary infection identified between 1995 2001 (group A; n = 76) 1999 B; 78). Sequence analysis assessed by population-based sequencing. Virus susceptibility to antiretroviral agents determined the PhenoSense assay (ViroLogic). Results The frequency resistance-associated mutations...
To assess the prevalence of menopausal symptoms among women prescribed hormone therapy (HT) using electronic medical record data from a regional healthcare organization. Retrospective Reliant Medical Group 1/1/2006-12/31/2011 were assessed for 102 randomly-selected patients. Study eligibility criteria included: females aged 45 to 65; oral or transdermal HT; no history breast cancer, venous thromboembolism, stroke, gynecological hysterectomy; continuously enrolled in health plan 1 year before...
Background Current statin use and symptoms among older adults in routine community practice have not been well characterized since the release of 2013 American College Cardiology/American Heart Association guideline. Methods Results We compared dosing between >75 ≤75 years old who were eligible for primary or secondary prevention without considering guideline‐recommended age criteria. The patients treated at 138 US practices Patient Provider Assessment Lipid Management (PALM) registry...
Background:In patients with acute coronary syndrome (ACS), alirocumab reduced the risk of recurring ischemic events. ODYSSEY J-IVUS assessed effect on atheroma volume in Japanese recently hospitalized ACS and hypercholesterolemia, using intravascular ultrasound imaging analysis.
Elevated lipoprotein(a) [Lp(a)] levels are considered a causal factor for cardiovascular disease. In phase 3 ODYSSEY trials, alirocumab reduced of low-density lipoprotein cholesterol (LDL-C) and Lp(a), with concomitant reductions in the risk major adverse events (MACE). We assessed whether lower on-study greater percentage Lp(a) associated MACE.Post-hoc analysis data pooled from 10 trials comparing control (placebo or ezetimibe) patients (n = 4983) disease and/or factors,...
The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapies for secondary prevention in patients with low-density lipoprotein ≥70 mg/dL or non-high-density ≥100 despite maximum tolerated statin therapy. Such are considered at very high risk (VHR) based on a history of >1 major atherosclerotic cardiovascular disease (ASCVD) event single ASCVD and multiple high-risk conditions. We investigated the association guideline-defined categories occurrence ischemic...
Bempedoic acid is an oral adenosine triphosphate citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) blood levels. The Cholesterol Lowering via acid, ACL-Inhibiting Regimen (CLEAR) Outcomes study demonstrated bempedoic reduced cardiovascular (CV) risk in patients at high for CV events who were unwilling or unable to take guideline-recommended doses of statins. To describe detailed safety information from CLEAR Outcomes, including the United States (US)...
Although intermittent episodes of low-level viremia are often observed in well-suppressed highly active antiretroviral therapy (HAART)-treated patients, the timing and amplitude viral blips have never been examined detail. We analyze here dynamics blips, i.e., plasma VL measurements >50 copies/ml, 123 HAART-treated patients monitored for a mean 2.6 years (range, 5 months to 5.3 years). The (+/- standard deviation) blip frequency was 0.09 +/- 0.11/sample, with about one-third showing no...
Despite the clinical benefits of combination antiviral therapy, whether maximal potency has been achieved with current drug combinations remains unclear. We studied first phase decay human immunodeficiency virus type 1 (HIV-1) RNA in plasma, one early indicator activity, after administration a novel lopinavir/ritonavir, efavirenz, tenofovir disoproxil fumarate, and lamivudine compared it that observed matched cohorts treated alternative regimens. On basis these comparisons, we conclude...
Objective: To assess the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy by following initial rate decline in plasma viral load, which is a measure therapy blocking replication. Design: An open-label, single-site study TDF 10 antiretroviral drug-naive chronically HIV-1-infected individuals. Methods: Antiviral responses were assessed at baseline and during 21 days with measuring HIV-1 RNA levels. The change from was determined both linear regression fitting to published model....
This sub-analysis of the ODYSSEY COMBO II study compared effects alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in high cardiovascular risk patients with or without diabetes mellitus (DM) receiving maximally tolerated statin therapy.COMBO was 104-week, double-blind (n = 720) enrolling documented atherosclerotic disease (ASCVD) and baseline LDL-C ≥70 mg/dL (1.8 mmol/L), ASCVD at ≥100 (2.6 mmol/L). Patients therapy were randomized (2:1) to alirocumab 75 mg every...